Anhydrous Docetaxel — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

4 Recruiting

8 Completed trials

8 Sponsors

17 Countries

Phase III

Phase II/III

Phase II

Phase III: 6 Phase II/III: 2 Phase II: 2 Phase I/II: 1 Phase III/IV: 1

Oversight events:

1 serious breach 7 temporary halts 1 urgent safety measure across 3 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 2 HER2 positive breast cancer 1 Ovarian epithelial cancer 1 Breast cancer 1 Ewing´s sarcoma metastatic 1 Extra-osseous Ewing´s sarcoma metastatic 1 Ovarian cancer recurrent 1 Ewing's sarcoma recurrent 1 Ewing's sarcoma 1 Extra-osseous Ewing's sarcoma recurrent 1 Prostate cancer metastatic 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 4 F. Hoffmann-La Roche AG 2 AstraZeneca AB 1 Fondation Franc.Cancerologie Digestive 1 Fondazione GONO G.I. 1 iOnctura SA 1 Karolinska Institutet 1 The University Of Birmingham 1

All trials

12 total

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting

2023-506662-31-00 Phase II 1 country Fondazione GONO G.I.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Phase III 3 countries Karolinska Institutet
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting

2024-516078-31-00 Phase II/III 10 countries The University Of Birmingham
MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended

2023-503539-16-00 Phase III 7 countries Merck Sharp & Dohme LLC
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended

2024-517741-14-00 Phase I/II 3 countries iOnctura SA
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Phase II 9 countries AstraZeneca AB
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended

2023-506177-35-00 Phase III/IV 10 countries Merck Sharp & Dohme LLC
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Phase III 13 countries Merck Sharp & Dohme LLC
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Phase III 8 countries Merck Sharp & Dohme LLC
Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oe… Ended

2024-515221-29-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive

Showing 1–12 of 12 trials

← All drugs A–Z